Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy
Abstract Little is known regarding coronavirus disease 2019 (COVID-19) clinical spectrum in non-Asian populations. We herein describe the impact of COVID-19 on liver function in 100 COVID-19 consecutive patients (median age 70 years, range 25–97; 79 males) who were admitted to our internal medicine unit in March 2020. We retrospectively assessed liver function tests, taking into account demographic characteristics and clinical outcome. A patient was considered as having liver injury when alanine aminotransferase (ALT) was > 50 mU/ml, gamma-glutamyl transpeptidase (GGT) > 50 mU/ml, or total bilirubin > 1.1 mg/dl. Spearman correlation coefficient for laboratory data and bivariable analysis for mortality and/or need for intensive care were assessed. A minority of patients (18.6%) were obese, and most patients were non- or moderate-drinkers (88.5%). Liver function tests were altered in 62.4% of patients, and improved during follow-up. None of the seven patients with known chronic liver disease had liver decompensation. Only one patient developed acute liver failure. In patients with altered liver function tests, $ PaO_{2} $/$ FiO_{2} $ < 200 was associated with greater mortality and need for intensive care (HR 2.34, 95% CI 1.07–5.11, p = 0.033). To conclude, a high prevalence of altered liver function tests was noticed in Italian patients with COVID-19, and this was associated with worse outcomes when developing severe acute respiratory distress syndrome..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Internal and emergency medicine - 15(2020), 8 vom: 10. Juli, Seite 1399-1407 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lenti, Marco Vincenzo [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
BKL: | |
---|---|
Themen: |
Acute respiratory failure |
doi: |
10.1007/s11739-020-02425-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR041781880 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR041781880 | ||
003 | DE-627 | ||
005 | 20230520012049.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201105s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11739-020-02425-w |2 doi | |
035 | |a (DE-627)SPR041781880 | ||
035 | |a (SPR)s11739-020-02425-w-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.80 |2 bkl | ||
100 | 1 | |a Lenti, Marco Vincenzo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Little is known regarding coronavirus disease 2019 (COVID-19) clinical spectrum in non-Asian populations. We herein describe the impact of COVID-19 on liver function in 100 COVID-19 consecutive patients (median age 70 years, range 25–97; 79 males) who were admitted to our internal medicine unit in March 2020. We retrospectively assessed liver function tests, taking into account demographic characteristics and clinical outcome. A patient was considered as having liver injury when alanine aminotransferase (ALT) was > 50 mU/ml, gamma-glutamyl transpeptidase (GGT) > 50 mU/ml, or total bilirubin > 1.1 mg/dl. Spearman correlation coefficient for laboratory data and bivariable analysis for mortality and/or need for intensive care were assessed. A minority of patients (18.6%) were obese, and most patients were non- or moderate-drinkers (88.5%). Liver function tests were altered in 62.4% of patients, and improved during follow-up. None of the seven patients with known chronic liver disease had liver decompensation. Only one patient developed acute liver failure. In patients with altered liver function tests, $ PaO_{2} $/$ FiO_{2} $ < 200 was associated with greater mortality and need for intensive care (HR 2.34, 95% CI 1.07–5.11, p = 0.033). To conclude, a high prevalence of altered liver function tests was noticed in Italian patients with COVID-19, and this was associated with worse outcomes when developing severe acute respiratory distress syndrome. | ||
650 | 4 | |a Acute respiratory failure |7 (dpeaa)DE-He213 | |
650 | 4 | |a Coronavirus |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hepatitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Severe acute respiratory syndrome |7 (dpeaa)DE-He213 | |
700 | 1 | |a Borrelli de Andreis, Federica |e verfasserin |4 aut | |
700 | 1 | |a Pellegrino, Ivan |e verfasserin |4 aut | |
700 | 1 | |a Klersy, Catherine |e verfasserin |4 aut | |
700 | 1 | |a Merli, Stefania |e verfasserin |4 aut | |
700 | 1 | |a Miceli, Emanuela |e verfasserin |4 aut | |
700 | 1 | |a Aronico, Nicola |e verfasserin |4 aut | |
700 | 1 | |a Mengoli, Caterina |e verfasserin |4 aut | |
700 | 1 | |a Di Stefano, Michele |e verfasserin |4 aut | |
700 | 1 | |a Cococcia, Sara |e verfasserin |4 aut | |
700 | 1 | |a Santacroce, Giovanni |e verfasserin |4 aut | |
700 | 1 | |a Soriano, Simone |e verfasserin |4 aut | |
700 | 1 | |a Melazzini, Federica |e verfasserin |4 aut | |
700 | 1 | |a Delliponti, Mariangela |e verfasserin |4 aut | |
700 | 1 | |a Baldanti, Fausto |e verfasserin |4 aut | |
700 | 1 | |a Triarico, Antonio |e verfasserin |4 aut | |
700 | 1 | |a Corazza, Gino Roberto |e verfasserin |4 aut | |
700 | 1 | |a Pinzani, Massimo |e verfasserin |4 aut | |
700 | 1 | |a Di Sabatino, Antonio |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Internal and emergency medicine |d Milan : Springer Milan, 2006 |g 15(2020), 8 vom: 10. Juli, Seite 1399-1407 |w (DE-627)SPR022112723 |w (DE-600)2378342-4 |x 1970-9366 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2020 |g number:8 |g day:10 |g month:07 |g pages:1399-1407 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11739-020-02425-w |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.80 |q ASE |
951 | |a AR | ||
952 | |d 15 |j 2020 |e 8 |b 10 |c 07 |h 1399-1407 |